RevealDx secures $3.4M from 4D Medical and global distribution for RevealAI-Lung across US, Europe, Australia, New Zealand

RevealDx raised $3.4 million from 4D Medical and struck a distribution agreement to have 4D Medical sell its RevealAI-Lung diagnostic software across the US, Europe, Australia, and New Zealand; the tool scores incidental lung nodules on CT using a Malignancy Similarity Index to guide radiologist follow-up. The software is validated on over 1,500 patients, holds CE, TGA and FDA clearances, and is reimbursable by Medicare under CPT codes 0721T and 0722T.

No comments yet.